Sector: Industrials
HEALTHCARE SERVICES GROUP INC · Meeting: May 26, 2026
Directors FOR
9
Directors AGAINST
0
Say on Pay
FOR
Auditor
AGAINST
Election of Directors
Independent director with relevant healthcare industry experience; no overboarding, attendance, or TSR trigger concerns — HCSG's 3-year return of +28.3% beats the peer median by only +1.2pp, well below the 50pp threshold required to trigger a No vote.
Independent director with industry and operational experience; no overboarding, attendance, or TSR trigger concerns given HCSG's strong relative performance versus its peer group.
Independent director with financial and operational expertise; serves on the Audit Committee and brings relevant financial qualifications; no policy triggers apply.
New nominee with no prior board tenure at HCSG; exempt from the TSR trigger as a first-time director; brings relevant legal and executive experience in the healthcare industry.
Independent director with operational and financial experience; no overboarding, attendance, or TSR trigger concerns; HCSG's 3-year outperformance versus peers is well within policy thresholds.
Independent CPA and Audit Committee Chairman with demonstrated financial expertise; no overboarding, attendance, or TSR trigger concerns.
Independent Board Chairman with financial and real estate experience; no overboarding, attendance, or TSR trigger concerns; HCSG's 3-year TSR of +28.3% exceeds the peer median by +1.2pp, which does not approach the 50pp threshold.
CEO and executive director; subject to the same TSR trigger as other directors, but HCSG's 3-year return of +28.3% outperforms the peer group median by +1.2pp — far below the 50pp threshold needed to trigger a No vote — so no TSR concern applies.
Director since 2025 and therefore exempt from the TSR trigger as a director within the past 24 months; the proxy discloses that his firm received $2.3 million in fees from HCSG in 2025, but NASDAQ independence rules are satisfied because those fees did not exceed 5% of the firm's total revenues, and the board has designated him as independent — no policy trigger fires, though shareholders should be aware of the commercial relationship.
All nine director nominees receive a FOR vote. HCSG's 3-year price return of +28.3% outperforms the company-disclosed compensation peer group median by +1.2pp, which is well below the 50pp underperformance threshold required to trigger Against votes for directors serving during this period. New nominee Thomas Gallagher is exempt from the TSR test as a first-time director. Thomas Whalen joined in 2025 and is also exempt. The board discloses a skills matrix, all audit committee members have financial expertise, and all committee members are independent. The one notable disclosure is the commercial relationship between Whalen's firm and HCSG ($2.3M in fees), which is within NASDAQ's independence safe harbor.
CEO
Theodore Wahl
Total Comp
$4,726,750
Prior Support
94%%
CEO Theodore Wahl received total compensation of approximately $4.73 million in 2025, which is reasonable for a CEO at a $1.4 billion healthcare services company and consistent with the prior year; his base salary has been frozen since 2016, which is a notable restraint. The pay structure is well-designed: a majority of total compensation comes from variable, at-risk elements including stock options, restricted stock units, performance stock awards (which vest based on relative total shareholder return versus a market index), and a performance-based cash bonus tied to income before taxes — all of which align executive pay with shareholder outcomes. HCSG's stock returned +96.7% over the past year and +28.3% over three years, outperforming both the company's peer group and the IHF — iShares U.S. Healthcare Providers ETF benchmark, and the prior Say on Pay vote received 94% shareholder support, indicating strong shareholder confidence in the program.
Auditor
Grant Thornton LLP
Tenure
33 yrs
Audit Fees
$1,348,000
Non-Audit Fees
$0
Grant Thornton LLP has served as HCSG's auditor since December 1992 — a tenure of approximately 33 years, which exceeds the 25-year threshold in our policy. The proxy does not provide a specific and compelling rationale for continued engagement, nor does it disclose a lead partner rotation schedule or a formal multi-year rotation plan. Non-audit fees are $0, so there is no independence concern on that dimension; the sole trigger here is the long-standing relationship, which raises concerns about whether the auditor maintains sufficient professional skepticism after more than three decades with the same management team.
The 2026 HCSG annual ballot presents four proposals: director elections (all nine nominees receive a FOR vote given solid relative stock performance versus peers), Say on Pay (FOR — well-structured pay-for-performance program with strong shareholder support history and a frozen CEO base salary since 2016), auditor ratification (AGAINST — Grant Thornton's 33-year tenure significantly exceeds the 25-year policy threshold with no compelling justification disclosed), and an equity plan share increase (not evaluated under current policy). The most notable governance concern on this ballot is the auditor tenure issue; all other governance signals are positive.
8 companies disclosed in 2026 proxy filing
